TENT AND TRADEMARK OFFICE IN THE UNITED ST

8888

8888

§ §

In re Applicant:

Dan GAZIT et al

Serial No.: 10/551,717

Filed:

July 14, 2006

For:

TAK1-MEDIATED INHIBITION OF

OSTEOGENESIS

Examiner:

Not yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Group Art Unit: 1632

Attorney

Docket: 30695

## INFORMATION DISCLOSURE STATEMENT -

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D Movnihan Registration No. 40,338

Dated: June 17, 2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE HILL OMB

TRADE	Complete if Known	
Substitute for form 1449A/PTO TRADE	Application Number	10/551,717
INFORMATION DISCLOSURE	Filing Date	July 14, 2006
STATEMENT BY APPLICANT	First Named Inventor	GAZIT Dan et al
(use as many sheets as necessary)	Art Unit	1632
	Examiner Name	Not Yet Assigned

Attorney Docket Number 30695 Sheet 1 | 3 U.S. PATENT DOCUMENTS Publication Date Name of Patentee or Pages, Columns, Lines, Where Examine Cite No. Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials\* Figures Appear Number-Kind Code<sup>2</sup> (ifknown) /BW/ US-2,609,347 02-2-1952 Wilson US-2,653,917 09-29-1953 Hammon et al. 3 US-2.659.935 11-24-1953 Hammon Wilson 4 US-2,664,366 12-29-1953 12-29-1953 Wilson 5 US-2,664,367 US-2,846,407 05-5-1958 Wilson 6 7 US-4,843,155 06-27-1989 Chomczynski US-5,509,042 04-16-1996 Mazess Q US-5,785,041 07-28-1998 Weinstein et al.

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>1</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ī
/BW/	10	JP 09-163990	06-24-1997	Irie			T
BW/	11	PCT WO 99/40202	08-12-1999	Sugita et	al.		T
7BW/	12	EP 1234880	08-28-2002	Matsumoto			Į
							†
Examine	r		L	L	Date	1	1
Signatur	e				Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Bridd's Codes or (USPTO Patint Documents at year usglo.gog or MPEP 001 0.4. "Either Drofto matti sused inde document, by the wo-later code (MPO Standard ST.3)." For Japanese patent documents, the indication of the year of the region of the Emperor must precide the serial number of the patent document. While the property of the patent document while the property of the patent document while the property of the patent document. While the property of the patent document while the property of the patent document where it is not document under VMPO standard ST.1 (if property). Applicant is to place a chacker what here if English language Translation is attached.

Transmission is executed.

USENT Dispression is required by 3 TCFR.197 and 1.96. The information is required to obtain or retain a benefit by the public which is to fis (and by the USENT Dispression) an application. Confederability is operanted by 3.0 USE. 122 and 37 UFR.1 14 libs collection is a estimated to lake 2 from the Complete including gathering, preparing, and submitting the completed application from to the USPTO. Three will vary depending upon the individual case. Any commentation in the amount of time your require to complete the including control of the your require to complete the including control of the your require to complete the including and the including control of the your require to complete the including and the including the your requirements. The public which is the public with the public which will be sent to the Chief Information Officer, by a Pleast and Trademark Office. U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

JUN 2 9 2007

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to formation unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO 10/551,717 Application Number INFORMATION DISCLOSURE Filing Date July 14, 2006 STATEMENT BY APPLICANT GAZIT Dan et al First Named Inventor (use as many sheets as necessary) Group Art Unit Examiner Name Not Yet Assigned Attorney Docket Number 30695 Sheet Of 3 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s),  $T^2$ Initials No. publisher, city and/or country where published. Shibuya et al. "Role of TAKI and TABI in BMP Signaling in Early Xenopus 13 /BW/ Development", The EMBO Journal, 17(4): 1019-1028, 1998. 14 Mochida et al. "ASK1 Inhibits Interleukin-1-Induced NF-KB Activity Through Disruption of TRAF6-TAK1 Interaction", The Journal of Biological Chemistry, 275(42): 32747-32752, 2000. Yoshida et al. "Negative Regulation of BMP/Smad Signaling by Tob in Osteoblasts", Cell, 103: 1085-1097, 2000. 16 Carninci et al. "Normalization and Subtraction of Cap-Trapper-Selected cDNAs to Prepare Full-Length cDNA Libraries for Rapid Discovery of New Genes", Genome Research, 10: 1617-1630, 2000. 17 Yamaguchi et al. "Identification of A Member of the MAPKKK Family as A Potential Mediator of TGF-B Signal Transduction", Science, 270: 2008-2011, 1995. 18 Hoffmann et al. "TGF-B-Activated Kinase-1 (TAK1), A MAP3K, Interacts With Smad Proteins and Interferes With Osteogenesis in Murine Mesenchymal Progenitors", Journal of Biological Chemistry, M503368200, P.1-46, 2005. Suzawa et al. "Cytokines Suppress Adipogenesis and PPAR-Gamma Function 19 Through the TAK1/TAB1/NIK Cascade", Nature Cell Biology, 5: 224-230, 2003 20 Kimura et al. "BMP2-Induced Apoptosis Is Mediated by Activation of the TAK1-P38 Kinase Pathway That Is Negatively Regulated by Smad6", The Journal of Biological Chemistry, 275(23): 17647-17652, 2000. P.17650, Col.1, Paragraph 3, P.17651, Col.2, Paragraph 2. Baulcombe "Diced Defence", Nature, 409; 295-296, 2001. Böhm "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", Journal of Computer-Aided Molecular Design, 6: 61-78, 1992. Boshart et al. "Reporter Constructs With Low Background Activity Utilizing the Cat Gene", Gene, 110: 129-130, 1992. Caffish et al. "Multiple Copy Simultaneous Search and Construction of Ligands in 24 Binding Sites: Application to Inhibitors of HIV-1 Aspartic Proteinase", Journal of Medical Chemistry, 36: 2142-2167, 1993. 25 Eisen et al. "HOOK: A Program for Finding Novel Molecular Architectures That Satisfy the Chemical and Steric Requirements of A Macromolecule Binding Site", Proteins: Structure, Function, and Genetics, 19: 199-221, 1994. 26 Gehlhaar et al. "De Novo Design of Enzyme Inhibitors by Monte Carlo Ligand Generation", Journal of Medical Chemistry, 38: 466-472, 1995. 27 Glišin et al. "Ribonucleic Acid Isolated by Cesium Chloride Centrifugation".

Biochemistry, 13(12): 2633-2637, 1974.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

considered include copy of this form with next communication to applicant.

Applicants unique ceitation designation number (opinions). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.07 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
USPTO or process) an application. Confidentably is governed by 39 U.S.C. 122 and 37 CFR 1.14 this collection is estimated to sale 5, bours to complete, including
gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount
of the comments of the



	F10/3D/000 (00-03)
	ed for use through 06/30/2006. OMB 0651-00
	Office: U.S. DEPARTMENT OF COMMERC
information unless it contains a va	lid OMB control number.
Co	mplete if Known
Application Number	10/551,717

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

Under the Paperwork Reduction Act of 1995, no persons are require

Filing Date July 14, 2006 STATEMENT BY APPLICANT GAZIT Dan et al First Named Inventor 1632 (use as many sheets as necessary) Group Art Unit Examiner Name Not Yet Assigned Of 3 Attorney Docket Number 30695 Sheet 3 I IMPRO I MILIDE DOCUMENTO

	1	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
nitials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
1	28	Hoffmann et al. "The T-Box Transcription Factor Brachyury Mediates Cartilage	
1	20	Development in Mesenchymal Stem Cell Line C3H10T1/2", Journal of Cell Science.	
	1	115: 769-781, 2002.	
	29	Kaminski "Computer-Assisted Drug Design and Selection", Advanced Drug Delivery	
		Reviews, 14: 331-337, 1994.	
	30	Kusanagi et al. "Characterization of A Bone Morphogenetic Protein-Responsive	
- 1	1	Smad-Binding Element", Molecular Biology of the Cell, 11: 555-565, 2000.	
	31	Ronis et al. "Skeletal Effects of Developmental Lead Exposure in Rats",	
- 1	1 -	Toxicological Sciences, 62: 321-329, 2001.	
	32	Meersseman et al. "The C-Terminal Domain of Mad-Like Signal Transducers Is	
1		Sufficient for Biological Activity in the Xenopus Embryo and Transcriptional	
- 1		Activation", Mechanisms of Devlopment, 61: 127-140, 1997.	
	33	Moon et al. "Computer Design of Bioactive Molecules: A Method for Receptor-	
- 1	""	Based De Novo Ligand Design", Proteins: Structure, Function, and Genetics, 11:	
- 1		314-328, 1991.	
	34	Puissant et al. "An Improvement of the Single-Step Method of RNA Isolation by	
ı		Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", BioTechniques,	
1		8(2): 148-149, 1990.	
	35	Suponitzky et al. "Differential Effects of Systemic Prostaglandin E2 on Bone Mass in	
1		Rat Long Bones and Calvariae", Journal of Endocrinology, 156: 51-57, 1998.	
	36	Verschueren et al. "SIPI, A novel Zinc Finger/Homeodomain Repressor, Interacts	
1		With Smad Proteins and Binds to 5'-CACCT Sequences in Candidate Target Genes",	
		The Journal of Biological Chemistry, 274(29): 20489-20498, 1999.	
1	37	Yang et al. "Evidence That Processed Small DsRNAs May Mediate Sequence-	
N/		Specific mRNA Degradation During RNAi in Drosophila Embryos", Current	
		Biology, 10: 1191-1200, 2000.	
	<u> </u>		

Signature	/Brian Whiteman/	Considered	03/03/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*\*EXAMINE\*\* Initials repetited considered, whitering or not classon is in conformance win where you. Under white introger classon into in conformance and not applicable to the property of th SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.